The Global Hepatitis Summit 2027 highlights global progress and innovations in preventing, treating, and eliminating viral and metabolic liver diseases through advances in immunology, virology, vaccines, and targeted therapies.
Key Topics
Public health interventions in liver diseases
Global achievements and failures in viral hepatitis elimination
Public health tools to eliminate viral hepatitis
Public health interventions to eliminate NAFLD/NASH
HCV elimination in Egypt: a success story
Innovations in liver disease therapy: present and future
Innovations in antiviral immunotherapy
Innovations in direct-acting antiviral therapies
Innovations in hepatocellular carcinoma therapy
Innovations in liver fibrosis and NASH therapy
Global Hepatitis Summit Debrief
HBV/HDV Debrief
HCV Debrief
HCC Debrief
NAFLD/NASH Debrief
New vaccine approaches for liver diseases
Towards an HCV vaccine
The story and future of RNA vaccines
Implementing global vaccination strategies
The future of therapeutic vaccines for viral infections
HCV immunology
Adaptive immune responses against HCV
Innate immune responses against HCV
HCV/flavivirus virology
HCV entry: lessons learnt for other viruses
What did HCV teach us on flavivirus virology
HBV/HDV immunology
Liver compartmentalization of anti-HBV immune responses
Immunological phenotyping of HBV infections
HBV/HDV virology
Update on HDV virology
Update on HBV virology
NASH targets for new therapies
Preclinical assessment of NASH compounds
Molecular targets for NASH therapy
HBV/HDV treatment targets
Targeting HBV RNAs for therapy
Targeting HBV capsids for therapy
HEV virology and persistence
Mechanisms of HEV persistance in immunodepressed patients
Update on HEV virology
HCC targets for new therapies
Immunological targets for HCC therapy
Molecular targets for HCC therapy
Liver inflammation and fibrogenesis
Mechanisms of liver fibrogenesis
Mechanisms of NAFLD/NASH-associated liver inflammation
